Topical bimatoprost for the treatment of eyebrow hypotrichosis.
Topical bimatoprost was FDA approved in December of 2008 for the treatment of eyelash hypotrichosis. Since its approval, some physicians have advocated the use of bimatoprost "off label" for hair growth in other areas, such as the scalp or eyebrows, but there has yet to be published scientific evidence to support this use. We report one of the first cases of significant eyebrow hair growth in a patient after use of topical bimatoprost for eyebrow hypotrichosis.
Mount Sinai Medical Center, New York, NY, USA. es@schweigerderm.com
Eric S
ES
Schweiger
Lisa
L
Pinchover
Robert M
RM
Bernstein
D000287:Administration, Topical; D000577:Amides / Q000008:administration & dosage*; D000069580:Bimatoprost; D003008:Cloprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005138:Eyebrows / Q000187:drug effects* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007039:Hypotrichosis / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D016896:Treatment Outcome
D000577:Amides; D003008:Cloprostenol; D000069580:Bimatoprost